No difference in HIV-1 integrase inhibitor resistance between CSF and blood compartments

Abstract Background Little is known about HIV-1 integrase inhibitor resistance in the CNS. Objectives This study aimed to evaluate CSF, as a marker of CNS, and compare it with plasma. Methods HIV was sequenced both plasma CSF for 59 patients. The clinical biological data were collected from routine care. Results Among patients, 32 (54.2%) under antiretroviral (ARV) treatment. median (IQR) RNA viraemic patients 5.32 (3.85–5.80) 3.59 (2.16–4.50) log10 copies/mL versus 4.79 (3.56–5.25) 3.80 (2.68–4.33) ARV-naive ARV-treated respectively. mainly infected non-B subtypes (72.2%) most prevalent recombinant form being CRF02_AG (42.4%). sequences presented mutations 9/27 (33.3%) 8/32 (25.0%) (L74I, n = 3; L74I/M, 1; T97A, E157Q, 4) 6; L74M, N155H, 1) Integrase similar those plasma, except 1/59 Conclusions work shows profiles CNS population